Menu
Recruiting NCT04259580

Calgary Registry for Advanced and Therapeutic Endoscopy

Observational Biliary Disease Pancreatic Diseases

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: Endoscopic retrograde pancreatography (ERCP).
Who it may be relevant to
Registry conditions: Biliary Disease, Pancreatic Diseases. Basic parameters: from 18 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
Canada
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Overview

The aim of the Calgary Registry for Advanced and Therapeutic Endoscopy (CReATE) is to be a high-fidelity prospective multi-centre registry. The study population consists of consecutive adult ERCP patients from September 2018 to August 2022. Informed consent is acquired for each patient. All relevant pre-procedural, procedural, peri-procedural and post-procedural data are captured in real time by a full-time third-party research assistant directly observing procedures. Outcomes are ascertained by comprehensive medical record review and patient phone interview 30 days after the index procedure. This registry also serves as a secure data collection platform for several currently recruiting prospective studies and randomized trials.

Interventions

  • Procedure Endoscopic retrograde pancreatography (ERCP)
    Endoscopic procedure to access biliary and/or pancreatic structures

Primary outcome measures

  • Rate of unplanned healthcare utilization [Time frame: 30 days]
Secondary outcome measures (4)
  • Rate of post-ERCP pancreatitis [Time frame: 30 days]
  • Rate of post-ERCP bleeding [Time frame: 30 days]
  • Rate of post-ERCP cholangitis or sepsis [Time frame: 30 days]
  • Technical success rates [Time frame: Immediate]

Eligibility criteria

Inclusion criteria

  • any standard indication for ERCP, in the absence of standard contraindications;
  • age 18 years or over;
  • ability and willingness to give informed consent to be included in the registry and/or to involvement in one (or more) prospective sub-studies, or accompaniment by a surrogate who is willing and able to provide consent.

Exclusion criteria

-none other than inverses of above.

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Study design

Observational model
Other

Study locations

Canada · 1 center
  • University of Calgary — Calgary

Publications

  • Mohamed R, Lethebe BC, Gonzalez-Moreno E, Kayal A, Bass S, Cole M, Turbide C, Chau M, Koury HF, Brenner DR, Hilsden RJ, Elmunzer BJ, Keswani RN, Wani S, Heitman SJ, Forbes N. Morphology of the major papilla predicts ERCP procedural outcomes and adverse events. Surg Endosc. 2021 Dec;35(12):6455-6465. doi: 10.1007/s00464-020-08136-9. Epub 2020 Nov 4. PMID 33146812

Identifiers

NCT: NCT04259580 · REB18-0410

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗